Target intelligence / Profile preview

RNA, U2 small nuclear 28, pseudogene (RNU2-28P)

Target
RNU2-28P
Molecular classification
Other (pseudogene)
01

Overview

RNU2-28P is a pseudogene that corresponds to the U2 small nuclear RNA (snRNA) family, specifically annotated as "RNA, U2 small nuclear 28, pseudogene". U2 snRNAs are components of the spliceosome, a cellular complex responsible for pre-mRNA splicing in eukaryotes[3]. However, RNU2-28P itself is a pseudogene, meaning that it is a DNA sequence similar to a gene but non-functional: it is not believed to produce functional RNA or protein products, does not participate directly in splicing, is not known to have any biological activity, and is not a therapeutic target[1]. RNU2-28P should not be confused with the genuine, functional U2 snRNA genes (such as RNU2-1 or RNU2-2), which encode catalytic RNA components of the spliceosome[2][3]. The “pseudogene” annotation indicates that RNU2-28P is not expected to play a direct role in biological processes or disease, and no known drugs, mechanisms of action, biomarkers, or safety concerns are associated with it[1]. Correction/limitation: RNU2-28P is not a bona fide gene or drug target and is often included in lists of non-functional genomic elements. If seeking a functionally relevant U2 snRNA, refer to RNU2-1 or RNU2-2, which are actively studied in the context of spliceosomal function and human disease[2]. Summary: RNU2-28P is a non-coding, non-functional pseudogene of the U2 snRNA family, not a protein, enzyme, receptor, or known therapeutic target[1].

Other names
RNU2-28PU2 small nuclear RNA 28 pseudogeneRNA, U2 snRNA 28, pseudogene

Beyond the preview

Go deeper on RNA, U2 small nuclear 28, pseudogene (RNU2-28P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U2 small nuclear 28, pseudogene (RNU2-28P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call